We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+26.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$494M
AUM Growth
+$67.8M
Cap. Flow
+$68.1M
Cap. Flow %
13.78%
Top 10 Hldgs %
52.79%
Holding
80
New
31
Increased
8
Reduced
10
Closed
27

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.7M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.1M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$12.1M
4
FOLD
Amicus Therapeutics
FOLD
+$11.4M
5
GYRE icon
Gyre Therapeutics
GYRE
+$11.2M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$15.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$9.37M

Sector Composition

Rank Sector Weight
1 Healthcare 74.74%
2 Miscellaneous 25.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABLX
76
DELISTED
Ablynx NV
ABLX
– –
-90,000
Closed -$2.25M
JUNO
77
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-150,000
Closed -$6.86M
ZGNX
78
DELISTED
Zogenix, Inc.
ZGNX
– –
-180,000
Closed -$7.21M
CELG
79
CALL
DELISTED
Celgene Corp
CELG
– –
-150,000
Closed -$15.7M
LJPC
80
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-200,000
Closed -$6.44M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Ghost Tree Capital held 80 positions worth $494M, up 16% from $426M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Ghost Tree Capital deployed $68.1M of net new capital in Q1 2018, opening 31 new positions and adding to 8 existing holdings. Its largest new stake was Sarepta Therapeutics: 235,000 shares worth $17.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 67% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $9.37M trimmed.

  • Ghost Tree Capital's largest Q1 2018 buy was Sarepta Therapeutics: 235,000 shares worth $17.4M.
  • Ghost Tree Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $10.9M increase.
  • Ghost Tree Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $9.37M.
  • Ghost Tree Capital fully exited Esperion Therapeutics in Q1 2018, selling an estimated $15.1M.
  • Ghost Tree Capital's ten largest holdings make up 53% of its $494M portfolio in Q1 2018.
  • Ghost Tree Capital opened 31 new positions and closed 27 in Q1 2018.
  • Ghost Tree Capital's portfolio value rose 16% quarter-over-quarter to $494M.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.